Ravulizumab · Ultomiris

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: Myasthenia Gravis, Thrombotic Microangiopathy, Paroxysmal Nocturnal Hemoglobinuria, Generalized Myasthenia Gravis, IgA Nephropathy

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Also approved (4)
US
  • the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody-positive.
Product first approved 2018Outside this platform's coverageFDA label
CA
  • Paroxysmal Nocturnal Hemoglobinuria (PNH) ULTOMIRIS® (ravulizumab for injection) is indicated for the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH). Atypical Hemolytic Uremic Syndrome (aHUS) ULTOMIRIS® (ravulizumab for injection) is indicated for the treatment of adult and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement- mediated thrombotic microangiopathy (TMA). Limitations of Use: ULTOMIRIS is not indicated for the treatment of patients with Shiga toxin...
Product first approved 2019Health Canada
EU
  • Paroxysmal nocturnal haemoglobinuria (PNH) in adults (initial EU authorisation)
Product first approved 2019EMA
JP
  • Treatment of paroxysmal nocturnal hemoglobinuria
Product first approved 2019PMDA

Development in Chronic Kidney Disease stopped (2026-04) after a negative readout. Development continues in another indication. Source

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (25)
Generalized Myasthenia Gravis
NCT05644561 · Alexion Pharmaceuticals, Inc.
2023-06-24 – 2028-06-30 · Generalized Myasthenia Gravis, gMG
What this study did
NCT07596784 · Alexion Pharmaceuticals, Inc.
2026-07-27 – 2027-08-24 · Generalized Myasthenia Gravis, gMG
What this study did
IgA Nephropathy
NCT07024563 · Alexion Pharmaceuticals, Inc.
2025-06-14 – 2030-04-19 · IgAN, IgAVN, Immunoglobulin A Nephropathy, Immunoglobulin A Vasculitis Associated Nephritis, Henoch-schonlein Purpura Nephritis, IgA Vasculitis
What this study did
Paroxysmal Nocturnal Hemoglobinuria
NCT06449001 · Alexion Pharmaceuticals, Inc.
2025-08-11 – 2028-03-10 · Paroxysmal Nocturnal Hemoglobinuria, PNH, Extravascular Hemolysis
What this study did
NCT06578949 · Alexion Pharmaceuticals, Inc.
2024-10-10 – 2025-12-22 · Paroxysmal Nocturnal Hemoglobinuria, PNH
What this study did
NCT03748823 · Alexion Pharmaceuticals, Inc.
2019-02-19 – 2023-08-31 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
NCT05131204 · Regeneron Pharmaceuticals
2022-10-06 – 2023-07-12 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
Thrombotic Microangiopathy
NCT04543591 · Alexion Pharmaceuticals, Inc.
2020-12-10 – 2026-03-20 · Thrombotic Microangiopathy
What this study did
NCT04557735 · Alexion Pharmaceuticals, Inc.
2020-12-07 – 2025-05-27 · Thrombotic Microangiopathy
What this study did
NCT04743804 · Alexion Pharmaceuticals, Inc.
2021-06-29 – 2022-12-22 · Thrombotic Microangiopathy
What this study did
Other / comorbidity
NCT07557420 · Alexion Pharmaceuticals, Inc.
2026-07-20 – 2028-09-19 · NMOSD, Neuromyelitis Optica Spectrum Disorder
What this study did
NCT04201262 · Alexion Pharmaceuticals, Inc.
2019-12-09 – 2024-10-31 · Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
What this study did
NCT04570397 · Brigham and Women's Hospital
2020-12-18 – 2023-11 · Covid19, Thrombotic Microangiopathies, Acute Kidney Injury
What this study did
NCT04248465 · Alexion Pharmaceuticals, Inc.
2020-03-30 – 2021-10-17 · Amyotrophic Lateral Sclerosis, ALS
What this study did
NCT04369469 · Alexion Pharmaceuticals, Inc.
2020-05-10 – 2021-04-08 · COVID-19 Severe Pneumonia, Acute Lung Injury, Acute Respiratory Distress Syndrome, Pneumonia, Viral
What this study did
Phase 2/3 (2)
Other / comorbidity
NCT05346354 · Alexion Pharmaceuticals, Inc.
2022-06-23 – 2029-03-30 · Neuromyelitis Optica Spectrum Disorder
What this study did
NCT04999020 · Alexion Pharmaceuticals, Inc.
2021-11-19 – 2024-05-08 · Dermatomyositis
What this study did
Phase 2 (4)
IgA Nephropathy
NCT04564339 · Alexion Pharmaceuticals, Inc.
2021-01-19 – 2025-08-18 · Lupus Nephritis, Immunoglobulin A Nephropathy
What this study did
Paroxysmal Nocturnal Hemoglobinuria
NCT04702568 · BioCryst Pharmaceuticals
2020-12-18 – 2023-10-04 · Paroxysmal Nocturnal Hemoglobinuria, PNH
What this study did
NCT02605993 · Alexion Pharmaceuticals, Inc.
2016-01-04 – 2022-01-12 · Paroxysmal Nocturnal Hemoglobinuria, PNH
What this study did
Other / comorbidity
NCT06333652 · Mayo Clinic
2027-04-01 – 2028-12-31 · Preeclampsia
What this study did
Phase 1/2 (1)
Paroxysmal Nocturnal Hemoglobinuria
NCT02598583 · Alexion Pharmaceuticals, Inc.
2015-11-12 – 2021-03-11 · PNH
What this study did
Phase 1 (5)
Other / comorbidity
NCT05396742 · Alexion Pharmaceuticals, Inc.
2018-08-09 – 2019-05-21 · Healthy
What this study did
NCT05288829 · Alexion Pharmaceuticals, Inc.
2016-08-19 – 2017-07-18 · Healthy
What this study did
NCT05288816 · Alexion Pharmaceuticals, Inc.
2016-04-18 – 2017-07-05 · Healthy
What this study did
NCT05288673 · Alexion Pharmaceuticals, Inc.
2015-07-28 – 2016-09-01 · Healthy
What this study did
NCT05288660 · Alexion Pharmaceuticals, Inc.
2014-08-27 – 2015-03-13 · Healthy
What this study did
Phase 4 (5)
Generalized Myasthenia Gravis
NCT07221838 · Alexion Pharmaceuticals, Inc.
2026-03-04 – 2027-08-27 · Generalized Myasthenia Gravis, gMG
What this study did
Paroxysmal Nocturnal Hemoglobinuria
NCT04320602 · Alexion Pharmaceuticals, Inc.
2021-04-14 – 2022-12-20 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
Other / comorbidity
NCT07010302 · Massachusetts General Hospital
2026-09-01 – 2030-05 · NMOSD
What this study did
NCT07308574 · Alexion Pharmaceuticals, Inc.
2025-12-19 – 2027-06-25 · aHUS, Atypical Hemolytic Uremic Syndrome
What this study did
NCT04390464 · Cambridge University Hospitals NHS Foundation Trust
2020-05-08 – 2022-05-01 · COVID19
What this study did
Used as active comparator (2)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Paroxysmal Nocturnal Hemoglobinuria
NCT04558918 · Novartis Pharmaceuticals
2021-01-25 – 2023-03-06 · Paroxysmal Nocturnal Hemoglobinuria (PNH)
What this study did
Phase 2 (1)
Paroxysmal Nocturnal Hemoglobinuria
NCT05116774 · BioCryst Pharmaceuticals
2021-12-06 – 2023-09-14 · Paroxysmal Nocturnal Hemoglobinuria (PNH)
What this study did

Competitive landscape

6 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Myasthenia Gravis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ravulizumab (Ultomiris): this drugApprovedMonoclonal antibodyComplement C5not yet gradedNo reviewed efficacy summary in this indication
Avacincaptad Pegol (Izervay)
Approved(overall)
RNA AptamerComplement C5
Reliable signal(overall)
No reviewed efficacy summary in this indication
Eculizumab (Soliris)ApprovedMonoclonal antibodyComplement C5Partial signal
NCT01997229: Myasthenia Gravis Activities of Daily Living Profile (MG-ADL): Change From Baseline in MG-ADL Total Score at Week 26 by Worst-Rank Analysis of Covariance (ANCOVA) (End of study (Week 26)): Eculizumab 56.6 scores on a scale (Standard Error 4.53) | Placebo 68.3 scores on a scale (Standard Error 4.49) missed
Efgartigimod Alfa (Vyvgart)ApprovedAntibody fragmentFcRnnot yet gradedNo reviewed efficacy summary in this indication
CemdisiranPhase 3RNA / oligonucleotideComplement C5not yet gradedNo reviewed efficacy summary in this indication
Descartes-08Phase 3Cell therapyBCMA (B-cell maturation antigen)not yet gradedNo reviewed efficacy summary in this indication
ImeroprubartPhase 3Monoclonal antibodyFcRnnot yet gradedNo reviewed efficacy summary in this indication
PovetaciceptPhase 2Protein / enzyme therapeuticBAFF / APRILnot yet gradedNo reviewed efficacy summary in this indication
Ublituximab (Briumvi)Phase 2Monoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
ABBV-6628
Phase 1/2(overall)
Antibody fragmentComplement C5
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(9 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Ultomiris (Ravulizumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (5)
May 2027 (1)
Phase 3Paroxysmal Nocturnal HemoglobinuriaRecruiting
Est. primary completion 2027-05-28 · NCT06449001 · CT.gov ↗
What to watch
June 2027 (1)
Phase 4aHUS, Atypical Hemolytic Uremic SyndromeRecruiting
Est. primary completion 2027-06-25 · NCT07308574 · CT.gov ↗
What to watch
August 2027 (2)
Phase 3Myasthenia GravisRecruiting
Est. primary completion 2027-08-24 · NCT07596784 · CT.gov ↗
What to watch
Phase 4Myasthenia GravisRecruiting
Est. primary completion 2027-08-27 · NCT07221838 · CT.gov ↗
What to watch
November 2027 (1)
Phase 3Delayed Graft Function, DGF, Kidney TransplantRecruiting
Est. primary completion 2027-11-30 · NCT06830798 · CT.gov ↗
What to watch
2028 (3)
September 2028 (1)
Phase 3NMOSD, Neuromyelitis Optica Spectrum DisorderRecruiting
Est. primary completion 2028-09-19 · NCT07557420 · CT.gov ↗
What to watch
November 2028 (1)
Phase 3IgA NephropathyRecruiting
Est. primary completion 2028-11-29 · NCT07024563 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2PreeclampsiaRecruiting
Est. primary completion 2028-12-31 · NCT06333652 · CT.gov ↗
What to watch
2030 (1)
January 2030 (1)
Phase 4NMOSDRecruiting
Est. primary completion 2030-01 · NCT07010302 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

21 October 2026ApprovalFDA grants accelerated approval to Ultomiris in IgA nephropathy
US, FDA · Source ↗
October 2026ApprovalFDA Boxed Warning on Ultomiris (BLA761108)
US, FDA · FDA · Source ↗
27 July 2026Topline resultALXN1210-TMA-313 (NCT04543591) Phase III missed its primary endpoint
AstraZeneca (Alexion, AstraZeneca Rare Disease) · Source ↗